Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute multiple life-saving opioid overdose ...

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (Emergent) for the ...

Under the terms of the six-year agreement, Emergent will add KLOXXADO® Nasal Spray to its naloxone product portfolio and will be responsible for all North America product sales and marketing.

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 ...

Milestone Pharmaceuticals Inc. announced an investor event on February 25, 2025, in New York to discuss its commercial launch plan for etripamil nasal spray, also known as CARDAMYST™, which is ...

The nasal spray "Neffy" is the first needle-free option for severe allergic reactions that the FDA has approved. The spray would be an alternative to EpiPens.

The US Food and Drug Administration approved the first nasal spray epinephrine drug for severe allergic reactions known as anaphylaxis, providing a needle-free alternative to EpiPens and similar ...

The FDA has approved a nasal spray, called neffy, to treat serious allergic reactions in adults and children who weigh at least 66 pounds. It should be available in the next few months.

--Emergent BioSolutions Inc. announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO ® Nasal Spray ...

The nasal spray "Neffy" is the first needle-free option for severe allergic reactions that the FDA has approved. The spray would be an alternative to EpiPens.

Alongside over-the-counter NARCAN ® Nasal Spray 4 mg, prescription KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute multiple life-saving opioid overdose ...

GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S ...